Related Experiment Videos

Trial of early neonatal hydrocortisone: two-year follow-up

Outi M Peltoniemi1, Aulikki Lano, Riina Puosi

  • 1Department of Pediatrics, University of Oulu, Oulu, Finland. outi.peltoniemi@mail.suomi.net

Neonatology
|October 22, 2008
PubMed

Insights

Early hydrocortisone (HC) treatment in preterm infants showed no adverse neurologic outcomes at 2 years. This study confirms the safety of HC for infants, with no increased risk of cerebral palsy.

Area of Science:

  • Neonatal care and developmental pediatrics.
  • Pharmacological interventions in premature infants.

Background:

  • Dexamethasone use in neonates is linked to increased cerebral palsy (CP) risk.
  • Early hydrocortisone (HC) may reduce bronchopulmonary dysplasia but requires long-term safety evaluation.
  • Confirming the long-term safety of early HC treatment in preterm infants is crucial.

Purpose of the Study:

  • To investigate the hypothesis that early hydrocortisone (HC) treatment does not negatively impact neurologic outcomes in very preterm infants.
  • To assess the long-term safety and neurodevelopmental effects of early HC administration.

Main Methods:

  • Follow-up data from a randomized trial of 10-day early HC or placebo treatment.
  • Measurement of serum cortisol levels pre-treatment to classify infants as low or high endogenous cortisol.
  • Meta-analysis of three trials involving 411 infants to evaluate CP rates and neurodevelopmental outcomes.

Main Results:

  • 98% of surviving infants (46) attended a 2-year follow-up; growth characteristics were similar across groups.
  • Developmental quotients (DQs) at 2 years were comparable between HC and placebo groups, regardless of endogenous cortisol levels.
  • Meta-analysis indicated no significant influence of HC on CP rates or survival without neurosensory/cognitive impairment.

Conclusions:

  • Early low-dose hydrocortisone (HC) administration demonstrated no adverse effects on neurodevelopment at 2 years of corrected age.
  • Findings support the safety of early HC treatment in very preterm infants.
  • Further research is needed to identify specific infant populations who may benefit most from neonatal HC.
Abstract

Related Concept Videos

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Hypersensitivity Reactions: Delayed Hypersensitivity Reactions01:29

Hypersensitivity Reactions: Delayed Hypersensitivity Reactions

Delayed-Type Hypersensitivity (DTH), or Type IV hypersensitivity, is a cell-mediated immune response. It occurs when T cells, rather than antibodies, mediate a reaction to specific antigens. It is characterized by a delayed onset (1-2 days) and involves the recruitment of macrophages to the inflammation site.The initiation of a DTH response begins with the sensitization of T cells. During this phase, which lasts at least 1-2 weeks, antigen-specific T cells are activated, clonally expanded, and...